贫血孕妇对铁剂治疗的反应对母婴结局的影响
该基于人群的队列研究(2011-2019年,2家分娩医院)纳入20690名孕妇,其中7416名(35.8%)贫血。贫血孕妇按口服铁剂治疗反应分为成功治疗组(Hgb≥11 g/dL)、难治组(Hgb<11 g/dL)和未治疗组,与无贫血参照组比较。成功治疗组早产和子痫前期的 odds 显著降低,难治组和未治疗组则显著升高。
要点
- 贫血孕妇中仅36.3%口服铁剂治疗成功,17.8%难治,45.9%未治疗。
- 成功治疗组早产 odds 显著低于参照组(aOR 0.59,95%CI 0.47-0.72)。
- 难治组和未治疗组的早产和子痫前期 odds 均显著高于参照组。
核心结论
- 口服铁剂成功治疗贫血与早产和子痫前期 odds 降低相关;难治性贫血孕妇结局与未治疗者相似,强调孕期监测铁剂治疗反应的重要性。
研究设计与样本
- 基于人群的队列研究(2011-2019年),使用包含2家分娩医院产科患者的机构数据库,纳入有充分产前保健的孕妇20690名。
- 贫血孕妇按入院分娩时美国妇产科医师学会(ACOG)贫血标准分层:成功治疗(Hgb≥11 g/dL)、难治(Hgb<11 g/dL)和未治疗,并与无贫血参照组比较。
- 采用卡方检验和逻辑回归分析,主要结局为早产和子痫前期。
主要发现
- 20690名孕妇中7416名(35.8%)贫血;贫血孕妇中1319名(17.8%)难治,2695名(36.3%)治疗成功,3402名(45.9%)未治疗。
- 成功治疗组早产发生率5.1% vs 参照组8.3%,调整后 odds ratio(aOR)0.59(95%CI 0.47-0.72);子痫前期5.9% vs 8.3%,aOR 0.75(95%CI 0.61-0.91)。
- 难治组早产 aOR 1.44(95%CI 1.16-1.76),未治疗组早产 aOR 1.45(95%CI 1.26-1.67);难治组子痫前期 aOR 1.54(95%CI 1.24-1.89),未治疗组子痫前期 aOR 1.44(95%CI 1.25-1.67)。
- 所有贫血组产后出血 odds 均升高,小于胎龄儿 odds 均降低;复合新生儿病率无差异。
关键数值与推荐
- 贫血诊断及治疗反应评估采用入院分娩时美国妇产科医师学会(ACOG)贫血标准:成功治疗为 Hgb≥11 g/dL,难治为 Hgb<11 g/dL。
临床怎么用
- 作者强调孕期监测铁剂治疗反应的重要性;成功治疗与早产和子痫前期 odds 降低相关,难治性贫血结局与未治疗者相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anemia during pregnancy is associated with increased risks of preterm birth, preeclampsia, cesarean delivery, and maternal morbidity. The most prevalent modifiable cause of pregnancy-associated anemia is iron deficiency. However, it is still unclear whether iron therapy can reduce the risks of adverse outcomes in women with anemia. OBJECTIVE: This study aimed to determine whether response to iron therapy among women with anemia is associated with a change in odds of adverse maternal and neonatal outcomes. STUDY DESIGN: This was a population-based cohort study (2011-2019) using an institutional database composed of obstetrical patients from 2 delivery hospitals. Patients with adequate prenatal care were classified as being anemic or nonanemic (reference). Patients with anemia were further stratified by success or failure of treatment with oral iron therapy using the American College of Obstetricians and Gynecologists criteria for anemia at the time of admission for delivery: successfully treated (Hgb≥11 g/dL) or unsuccessfully treated ("refractory;" Hgb<11 g/dL). All categories of women with anemia categories were compared with the reference group of women without anemia using chi-square and logistic regression analyses. The primary outcomes were preterm birth and preeclampsia. RESULTS: Among the 20,690 women observed, 7416 (35.8%) were anemic. Among women with anemia, 1319 (17.8%) were refractory to iron therapy, 2695 (36.3%) had a successful response to therapy, and 3402 (45.9%) were untreated. Successfully treated patients with anemia had a significant reduction in the odds of preterm birth (5.1% vs 8.3%; adjusted odds ratio, 0.59; 95% confidence interval, 0.47-0.72) and preeclampsia (5.9% vs 8.3%; adjusted odds ratio, 0.75; 95% confidence interval, 0.61-0.91). Refractory and untreated patients had significantly increased odds of preterm birth (adjusted odds ratio, 1.44 [95% confidence interval, 1.16-1.76] and 1.45 [95% confidence interval, 1.26-1.67], respectively) and preeclampsia (adjusted odds ratio, 1.54 [95% confidence interval, 1.24-1.89] and 1.44 [95% confidence interval, 1.25-1.67], respectively). All groups of women with anemia had increased odds of postpartum hemorrhage and decreased odds of delivering a small for gestational age neonate. There was no difference in composite neonatal morbidity. CONCLUSION: Successful treatment of anemia with oral iron therapy was associated with a reduction in the odds of preterm birth and preeclampsia. Women with refractory anemia had similar outcomes to those who were untreated, emphasizing the importance of monitoring response to iron therapy during pregnancy.
引用
- Detlefs SE, Jochum MD, Salmanian B, et al. The impact of response to iron therapy on maternal and neonatal outcomes among pregnant women with anemia. Am J Obstet Gynecol MFM. 2022. PMID: 35033748. doi:10.1016/j.ajogmf.2022.100569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。